Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
1.
RFO UPF ; 28(1)20230808. ilus
Artigo em Português | LILACS, BBO - Odontologia | ID: biblio-1516306

RESUMO

Objetivo: Apresentar as modalidades de tratamentos conservadoras e minimamente invasivas mais usadas disponíveis no arsenal terapêutico das desordens temporomandibulares (DTM). Revisão da literatura: Os objetivos do tratamento invariavelmente incluem redução da dor, diminuição das atividades parafuncionais e restauração da função. Dentre as alternativas conservadoras e minimamente invasivas, podemos citar os dispositivos interoclusais, exercícios terapêuticos, eletrofototermoterapia, agulhamento seco e infiltração de anestésicos locais em pontos gatilho, injeção de sangue autógeno para controle da luxação mandibular, terapia cognitivo comportamental, toxina botulínica, viscossuplementação, controle farmacológico da dor aguda e crônica. As DTMs afetam uma proporção significativa da população. Somente após o fracasso das opções não invasivas é que devem ser iniciados tratamentos mais invasivos e irreversíveis. No entanto, algumas condições, como a anquilose e neoplasias, por exemplo, são essencialmente tratadas cirurgicamente e tentativas de tratamentos conservadores podem trazer piora na qualidade de vida ou risco de morte. Considerações finais: Uma abordagem de equipe multidisciplinar para o manejo é essencial no cuidado fundamental de todos os pacientes com DTM, para que o tratamento possa ser especificamente adaptado às necessidades individuais do paciente.


Aim: To present the most widely used conservative and minimally invasive treatment modalities available in the therapeutic arsenal for temporomandibular disorders (TMD). Literature review: Treatment goals invariably include pain reduction, reduction of parafunctional activities and restoration of function. Among the conservative and minimally invasive alternatives, we can mention interocclusal devices, therapeutic exercises, electrophototherapy, dry needling and infiltration of local anesthetics in trigger points, autogenous blood injection to control mandibular dislocation, cognitive behavioral therapy, botulinum toxin, viscosupplementation, pharmacological control of acute and chronic pain. TMD affects a considerable proportion of the population. Only after non-invasive options have failed should more invasive and irreversible treatments be initiated. However, some conditions, such as ankylosis and neoplasms, for example, are treated surgically and attempts at conservative treatments can lead to worsening quality of life or risk of death. Conclusions: A multidisciplinary team approach to management is essential in the fundamental care of all TMD patients, so that treatment can be specifically tailored to the patient's individual needs.


Assuntos
Humanos , Dor Facial/terapia , Transtornos da Articulação Temporomandibular/terapia , Transtornos da Articulação Temporomandibular/fisiopatologia , Placas Oclusais , Viscossuplementação/métodos , Tratamento Conservador/métodos , Agulhamento Seco/métodos
3.
Sci Rep ; 12(1): 17976, 2022 10 26.
Artigo em Inglês | MEDLINE | ID: mdl-36289252

RESUMO

Viscosupplementation (VS) of the temporomandibular joint (TMJ) aims to treat temporomandibular dysfunction (TMD) by stimulating synovial cells to improve intracapsular lubrication. The purpose of the present study was to assess a VS protocol planned with the aid of cone-beam computed tomography (CBCT) and checked by ultrasonography (US). The study was carried out in 3 stages. The first was to check the correspondence between the proposed facial reference points and the osseous components of the joint by means of CBCT. In the second stage, the upper and lower compartments of 20 TMJs of fresh frozen cadavers were injected with coloured liquids, and the accuracy of the technique was confirmed by dissecting the anatomical specimens. The third stage consisted of VS in 10 patients (20 TMJs), with real-time verification of the location of the needle tip by means of ultrasonography. CBCT confirmed the correct locations of the marked points used in the proposed VS protocol. The dissections showed that 13 of the 14 injections effectively reached the upper and lower compartments. The location of the needle tip was effectively verified by ultrasonography, confirming the correct access to both compartments. The proposed protocol was effective for accessing the upper and lower compartments of the TMJ. The evaluated protocol proved to be accurate, safe and clinically reproducible means of VS in the upper and lower compartments of the TMJ.


Assuntos
Transtornos da Articulação Temporomandibular , Viscossuplementação , Humanos , Transtornos da Articulação Temporomandibular/diagnóstico por imagem , Transtornos da Articulação Temporomandibular/tratamento farmacológico , Articulação Temporomandibular/diagnóstico por imagem , Tomografia Computadorizada de Feixe Cônico/métodos , Ultrassonografia
4.
J. bras. econ. saúde (Impr.) ; 14(Suplemento 2)20220800.
Artigo em Inglês | LILACS, ECOS | ID: biblio-1412749

RESUMO

Objective: To evaluate the micro-costing of viscosupplementation procedures compared to different infiltration regimens. Methods: This study compared, through the Time-Driven ActivityBased Costing method, the micro-costing of these different application regimens using national cost averages as a basis for calculation in a medium-sized outpatient service. Results: The results demonstrated that the difference in costs with the single application is 31.47% less for three and 119.13% for five applications. Conclusions: No study showed a superiority of the five-application regimen over the three-application regimen, which leads one to believe that there is no justification for this procedure from an economic or quality-of-life point of view.


Objective: Avaliar o microcusteio dos procedimentos de viscossuplementação do joelho em diferentes regimes de aplicação. Métodos: Este estudo comparou, por meio do método Time-Driven Activity-Based Costing, o microcusteio desses diferentes regimes de aplicação, usando com base de cálculo médias nacionais de custo em um serviço ambulatorial de porte médio. Resultados: Os resultados encontrados demonstraram que a diferença nos custos com a aplicação única é 31,47% menor para três aplicações e 119,13% para cinco aplicações. Conclusão: Em nenhum estudo houve superioridade do regime de cinco aplicações ao regime de três, fato que leva a acreditar que não há nenhuma justificativa para esse procedimento do ponto de vista econômico ou de qualidade de vida do paciente.


Assuntos
Osteoartrite , Alocação de Custos , Viscossuplementação
5.
Québec; INESSS; janv. 2022.
Não convencional em Francês | BRISA/RedTESA | ID: biblio-1367476

RESUMO

MANDAT: L'Institut national d'excellence en santé et en services sociaux (INESSS) a reçu le mandat du Bureau de l'innovation de produire un avis sur la pertinence d'inclure les produits SynviscMD et Synvisc-OneMD au sein de la couverture du régime public pour les patients atteints d'arthrose du genou. DÉMARCHE D'ÉVALUATION: Une revue des données issues de la littérature et de celles fournies par le fabricant a été réalisée afin de documenter l'efficacité, l'innocuité et l'efficience des produits SynviscMD et Synvisc-OneMD. Des données expérientielles et contextuelles issues de la consultation d'experts sont aussi présentées. De plus, la perspective de patients atteints d'arthrose du genou a été obtenue au moyen d'un questionnaire élaboré par l'INESSS et diffusé par la Société de l'arthrite. BESOIN DE SANTÉ: La prévalence de l'arthrose du genou s'établit à environ 4,0 % dans la population québécoise âgée de plus de 20 ans. La nature évolutive de cette maladie a des répercussions grandissantes sur la qualité de vie des patients, leur fonctionnalité et leur autonomie. Il n'existe actuellement pas de traitement curatif pour l'arthrose. La prise en charge vise à soulager les symptômes et à maintenir une certaine fonctionnalité et consiste en l'utilisation concomitante de divers modes d'intervention. Toutefois, celle-ci ne permet de combler que partiellement les besoins de santé et une minorité de traitements sont accessibles ou couverts par le système de santé publique. Certains enjeux d'équité d'accès se posent dans la mesure où des patients n'ayant pas de moyens financiers ou d'assurances privées ont accès à moins d'options de traitements et de services. Certains patients peuvent donc se retrouver dans une impasse thérapeutique pendant plusieurs années, ce qui peut grandement affecter leur qualité de vie. PRODUITS EN ÉVALUATION: Les produits SynviscMD et Synvisc-OneMD sont des agents de viscosupplémentation identiques qui se distinguent par leur régime d'administration, soit par injection intraarticulaire à raison de 3 injections de 2 ml à intervalle d'une semaine pour SynviscMD ou d'une seule injection de 6 ml pour Synvisc-OneMD. SynviscMD et Synvisc-OneMD sont des options de traitement de l'arthrose depuis 22 et 12 ans respectivement, et disponibles au Québec pour plusieurs indications, y compris l'arthrose du genou, la coxarthrose, l'arthrose de la cheville et de l'épaule. Les experts mentionnent que le Synvisc-OneMD serait majoritairement utilisé par rapport au SynviscMD, notamment pour limiter le nombre d'injections. La viscosupplémentation pour le traitement de l'arthrose du genou avait déjà fait l'objet d'une évaluation en 2007 par l'Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS). L'agence avait conclu que, compte tenu de l'efficacité modeste de cette modalité thérapeutique par rapport au placébo, de son coût relativement élevé et des ressources professionnelles additionnelles nécessaires pour l'administrer, il n'était pas alors justifié d'envisager le financement public de la viscosuppléance pour l'ensemble des patients souffrant de gonarthrose au Québec.


Assuntos
Humanos , Osteoartrite do Joelho/tratamento farmacológico , Viscossuplementação/instrumentação , Avaliação em Saúde , Análise Custo-Benefício
6.
Artrosc. (B. Aires) ; 29(1): 14-21, 2022.
Artigo em Espanhol | LILACS, BINACIS | ID: biblio-1369635

RESUMO

Objetivos: La osteoartrosis (OA) es una artropatía incurable mono o poliarticular. En la rodilla es la enfermedad degenerativa más común, con gran incidencia de los factores mecánicos. El arsenal terapéutico para el manejo de la OA de rodilla (OAR) comprende medidas no farmacológicas, farmacológicas, medicación de técnicas intraarticulares y cirugía. Los objetivos de este trabajo fueron evaluar la eficacia en términos de dolor, función articular y calidad de vida de los pacientes infiltrados con ácido hialurónico (AH) de alto peso molecular (PM), doblemente reticulado (Cientific Synovial®, en adelante: CS) así como la seguridad de su uso. Adicionalmente se intentó objetivar el tiempo libre de prótesis en pacientes con esta indicación. Materiales y métodos: Se efectuó un diseño pre y post (un solo grupo) para pacientes con gonartrosis. Se analizó una muestra de cuarenta y seis pacientes (n = 46) a quienes se dividió en dos grupos según clasificación de Kellgren-Lawrence (KL). Un grupo KL 1­2 fue infiltrado con AH 40 mg (CS40), y otro grupo KL 3­4 fue infiltrado con AH 60 mg (CS60). A todos los pacientes se les suministró el cuestionario KOOS-12 (Knee injury and Osteoarthritis Outcome Score) pre y postinfiltración y se efectuó estadística descriptiva e inferencial apropiada. Conclusiones: el AH de alto PM y doblemente reticulado (Cientific Synovial®) mejoró estadística y clínicamente todos los parámetros de eficacia analizados por medio del cuestionario KOOS-12. El preparado se mostró seguro y sin aparición de efectos adversos de relevancia. Tanto en los pacientes con indicación previa de reemplazo total de rodilla (RTR) rechazada (n = 12) como en el resto de los pacientes de la muestra se verificó la supervivencia libre de prótesis hasta el final del estudio


Objectives: Osteoarthrosis (OA) is an incurable mono or polyarticular arthropathy and in the knee it is the most common degenerative disease with a high incidence of mechanical factors. The therapeutic arsenal for the management of knee OA (OAR) includes non-pharmacological and pharmacological measures, medication and intra-articular techniques, and surgery. The objectives of this study were to evaluate the efficacy in terms of pain, joint function and quality of life of patients infiltrated with double cross-linked high molecular weight (MW) hyaluronic acid (HA) (Cientific Synovial®, ­CS­) as well as the safety of its use. Additionally, we tried to objectify the prosthesis-free time in patients with this indication. Materials and methods: a pre - post design (single group) was carried out for patients with knee osteoarthritis. A sample of fortysix patients (n = 46) was analyzed who were divided into two groups according to the Kellgren-Lawrence (KL) classification. A group KL 1­2 was infiltrated with HA 40 mg (CS40) and another group KL 3­4 was infiltrated with HA 60 mg (CS60). All patients filled out the KOOS-12 questionnaire (Knee injury and Osteoarthritis Outcome Score) pre and post infiltration and appropriate descriptive and inferential statistics were performed. Conclusions: The double-crosslinked, high-MW HA (Cientific Synovial®) improved statistically and clinically all the efficacy parameters analyzed using the KOOS-12 questionnaire. The preparation was shown to be safe and without the appearance of significant adverse effects. Both in the patients with a previous indication for total knee replacement (TKR) rejected (n = 12), as in the rest of the patients in the sample, prosthesis-free survival was verified until the end of the study


Assuntos
Resultado do Tratamento , Osteoartrite do Joelho/terapia , Viscossuplementação , Ácido Hialurônico/uso terapêutico
7.
Clinics (Sao Paulo) ; 76: e2840, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33909828

RESUMO

OBJECTIVES: Arthrocentesis is the simplest surgical intervention for the temporomandibular joint (TMJ). It can be performed on an outpatient basis at a low cost and with low morbidity. The objective is to release the articular disc by disrupting the adhesion formed between its surfaces and the mandibular fossa through hydraulic pressure generated by irrigation of the upper compartment of the TMJ. Viscosupplementation with hyaluronic acid during or after arthrocentesis improves clinical outcomes, increases mouth opening, and reduces pain levels. The aim of this study was to evaluate the efficiency of arthrocentesis plus hyaluronic acid viscosupplementation through clinical examination and preoperative magnetic resonance imaging in patients with unilateral disc displacement without reduction (DDwoR). METHODS: This analytical retrospective cross-sectional study clinically and radiologically evaluated 72 patients of both sexes with unilateral DDwoR. The following data were collected: sex, pain, age, duration of pain, maximum mouth opening, and patient pain perception on a visual analog scale. TMJ arthrocentesis was performed only once for each of the indicated joints. Data were collected before arthrocentesis (baseline) and at 7, 14, 30, 60, 90, and 180 days after the procedure (final evaluation). RESULTS: Between the baseline and final evaluation, there was a significant reduction in pain (p=0.001) and restoration of articular function. In addition, there was a significant increase in maximum mouth opening (p=0.001). CONCLUSION: Patients with DDwoR undergoing arthrocentesis combined with hyaluronic acid injection showed significant improvement in the perceived pain and maximum mouth opening in the mid-term follow-up periods.


Assuntos
Luxações Articulares , Viscossuplementação , Artrocentese , Estudos Transversais , Feminino , Humanos , Masculino , Amplitude de Movimento Articular , Estudos Retrospectivos , Disco da Articulação Temporomandibular , Resultado do Tratamento
8.
J. oral res. (Impresa) ; 10(2): 1-10, abr. 30, 2021. ilus, tab
Artigo em Inglês | LILACS | ID: biblio-1382212

RESUMO

Objetive: The degenerative diseases of the tempo-romandibular joint (TMJ) are characterized by a progressive destruction of the articular tissues of the condyle and the glenoid fossa. The main aim of this review is to describe the effectiveness of the hyaluronic acid (HA) in the treatment of degenerative diseases of the TMJ in accordance with the available scientific evidence. Material and Methods: A literature search was made in the following databases EBSCO, Pubmed, Cochraneand Trip Database, using the keywords hyaluronic, hyaluronan, NaH, hyaluronate, TMJ, TMD, CMD, craniomandibular, orofacial pain and temporomandibular. There were no date or language restrictions applied. Results: After applying inclusion and exclusion criteria, 14 studies were included in this review (11 randomized controlled clinical trials and 3 non-randomized clinical trials). Conclusion: The studies reported a decrease in pain and improvement in functional parameters after treatment of TMJ osteoarthritis with HA . The use of arthrocentesis associated with the administration of HA provides effects synergistic, reaching a superiority the protocols with multiple injections with respect to those of a single session. The adverse effects related to the injection of HA with or without associated arthrocentesis were minor and transitory.


Resumen: Objetivo: Las enfermedades degenerativas de la articulación temporomandibular (ATM) se caracterizan por una destrucción progresiva de tejidos articulares en el cóndilo y la fosa glenoidea. El objetivo principal de esta revisión es describir la efectividad del uso de ácido hialurónico en el tratamiento de enfermedades degenerativas de la articulación temporomandibular de acuerdo con la evidencia científica disponible. Material y Métodos: Se realizó una búsqueda de la literatura en las bases de datos electrónicas EBSCO, PubMed, Cochrane y Trip Database, utilizando las palabras claves hyaluronic, hyaluronan, NaH, hyaluronate, tmj, tmd, cmd, craniomandibular, orofacial pain y temporomandibular, sin límite de fecha ni de idioma hasta Mayo del año 2020, complementada con una búsqueda retrógrada. Resultados: Con base en los criterios de inclusión y exclusión, 14 estudios fueron incluidos en esta revisión (11 ensayos clínicos controlados aleatorizados y 3 ensayos clínicos controlados no aleatorizados). Conclusión: Los estudios reportaron una disminución del dolor y mejora en los parámetros funcionales luego del tratamiento de osteoartritis de la ATM con AH. El uso de artrocentesis asociada a la administración del AH provee efectos sinérgicos, alcanzando una superioridad los protocolos con múltiples inyecciones con respecto a aquellos de una sola sesión. Los efectos adversos relacionados con la inyección de AH con o sin artrocentesis asociada fueron menores y transitorios.


Assuntos
Humanos , Osteoartrite/tratamento farmacológico , Transtornos da Articulação Temporomandibular/tratamento farmacológico , Ácido Hialurônico/administração & dosagem , Dor Facial , Viscossuplementação , Artrocentese
9.
Clinics ; Clinics;76: e2840, 2021. tab
Artigo em Inglês | LILACS | ID: biblio-1249590

RESUMO

OBJECTIVES: Arthrocentesis is the simplest surgical intervention for the temporomandibular joint (TMJ). It can be performed on an outpatient basis at a low cost and with low morbidity. The objective is to release the articular disc by disrupting the adhesion formed between its surfaces and the mandibular fossa through hydraulic pressure generated by irrigation of the upper compartment of the TMJ. Viscosupplementation with hyaluronic acid during or after arthrocentesis improves clinical outcomes, increases mouth opening, and reduces pain levels. The aim of this study was to evaluate the efficiency of arthrocentesis plus hyaluronic acid viscosupplementation through clinical examination and preoperative magnetic resonance imaging in patients with unilateral disc displacement without reduction (DDwoR). METHODS: This analytical retrospective cross-sectional study clinically and radiologically evaluated 72 patients of both sexes with unilateral DDwoR. The following data were collected: sex, pain, age, duration of pain, maximum mouth opening, and patient pain perception on a visual analog scale. TMJ arthrocentesis was performed only once for each of the indicated joints. Data were collected before arthrocentesis (baseline) and at 7, 14, 30, 60, 90, and 180 days after the procedure (final evaluation). RESULTS: Between the baseline and final evaluation, there was a significant reduction in pain (p=0.001) and restoration of articular function. In addition, there was a significant increase in maximum mouth opening (p=0.001). CONCLUSION: Patients with DDwoR undergoing arthrocentesis combined with hyaluronic acid injection showed significant improvement in the perceived pain and maximum mouth opening in the mid-term follow-up periods.


Assuntos
Humanos , Masculino , Feminino , Luxações Articulares , Viscossuplementação , Estudos Transversais , Estudos Retrospectivos , Amplitude de Movimento Articular , Resultado do Tratamento , Disco da Articulação Temporomandibular , Artrocentese
10.
Adv Rheumatol ; 60: 26, 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1130806

RESUMO

Abstract Background: Injection of Hylan G-F20 (HY) into joints may provoke local flares, which mechanisms may involve reaction to protein contaminants. We have previously developed a protein-free saline-soluble galactomannan derived from guar gum (GM) that displays both analgesia and chondroprotection in experimental osteoarthritis (OA). We now demonstrate that both GM and Hylan G-F20 (HY) promote mild synovitis with cytokine release after intra-articular injection. Methods: Mice received 100 μg/25 μL GM or HY or saline into the knees. Joint pain was evaluated using von Frey test; cell influx, interleukin (IL)-1, IL-6, and CXCL-1 (pg/mL) levels were assessed in joint lavage at 6 h. Synovia were excised for histopathology. Results: Neither GM nor HY after being given into mice knee joints induced pain albeit promoting mild cell influx into joint washings as well as mild synovitis at histology, with no damage to the underlying cartilage. HY but not GM promoted IL-1 release into mice joints. Both compounds induced IL-6 and CXCL-1 release. Conclusion: Intra-articular injection of HY or GM promote acute transient synovitis whilst not provoking detectable significant joint damage. Local administration of these polysaccharides induces acute intra-articular release of inflammatory cytokines, which may account for joint flares following viscosupplementation.(AU)


Assuntos
Animais , Camundongos , Osteoartrite/fisiopatologia , Polissacarídeos/administração & dosagem , Viscossuplementação/instrumentação , Ácido Hialurônico/administração & dosagem
11.
Clinics (Sao Paulo) ; 74: e1207, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31778431

RESUMO

OBJECTIVES: This study aimed to evaluate the clinical outcomes of intra-articular infiltration with hyaluronic acid and dexamethasone alone and in combination in the treatment of knee osteoarthritis (OA). METHOD: This prospective randomized trial evaluated 44 patients undergoing treatment for OA. Patients were selected through clinical and radiological analysis using the American College of Rheumatology criteria. We included patients aged between 50 and 70 years who presented with K-L stage ≤2 knee OA and normal limb alignment. Patients with a previous history of knee injury (ligamentous, meniscal or traumatic), infection, patellofemoral OA or chondroprotective drug use in the previous year were excluded. Participants were randomized into 3 groups and underwent treatment with viscosupplementation (VS, n=16), viscosupplementation plus dexamethasone (VD, n=16) or dexamethasone (DX, n=12). All patients were evaluated before and 6 weeks, 3 months and 6 months after infiltration. Analysis included a physical examination, the Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire (total score and domain subscores) and an evaluation of knee extensor and flexor strength and proprioception using an isokinetic dynamometer. RESULTS: VS significantly improved the WOMAC total score and subscores for pain, stiffness and function for up to 6 months after infiltration. It also improved knee extensor and flexor strength during the same period. Proprioception was not affected by any of the treatments. CONCLUSIONS: VS alone improved pain, stiffness and function according to the WOMAC total score and subscores and improved knee extensor and flexor strength, but not proprioception, for up to six months after infiltration. These findings suggest that VS has a positive effect on quadriceps arthrogenic inhibition.


Assuntos
Dexametasona/administração & dosagem , Ácido Hialurônico/administração & dosagem , Osteoartrite do Joelho/tratamento farmacológico , Dor/tratamento farmacológico , Viscossuplementação/métodos , Idoso , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento
12.
Cad Saude Publica ; 35(10): e00098618, 2019.
Artigo em Português | MEDLINE | ID: mdl-31596396

RESUMO

Knee osteoarthritis affects 3.8% of the world population and manifests as pain, edema, stiffness, and reduced joint function, impacting the patient's quality of life. Treatment consists of the pharmacological, non-pharmacological, and surgical modalities. Viscosupplementation (intraarticular hyaluronate) has been proposed to relieve symptoms and potentially postpone surgery. This study estimated the budget impact of the association of this drug and non-surgical treatment (standard treatment) from the perspective of the Brazilian Unified National Health System. Based on the assumption that 5% of patients proceed to treatment and on the direct costs of the pharmacological and non-pharmacological modalities, the authors calculated the reference and alternative scenarios that compared the different treatment options in a three-year timeline. The principal analysis estimated an incremental budget impact of approximately BRL 126 million (U$ 32 million) for one vial of hyaluronate a year and BRL 252 million (USD 64 million) for two vials a year. Diacerein, an oral chondroprotector, assessed as an alternative, showed a budget impact of BRL 334 million (USD 86 million) in relation to standard treatment, representing a 24% cost increase compared to two vials a year of hyaluronate, making it less economically advantageous. Viscosupplementation can provide better quality of life for patients, reduce costs for the health system, and optimize the flow of care in health services. The estimates presented in this study can assist administrators in the best use of resources and thus in decision-making on the technology's incorporation.


A osteoartrite de joelho afeta cerca de 3,8% da população mundial e se manifesta por dor, edema, rigidez e redução da função articular, impactando na qualidade de vida do paciente. O tratamento consiste na modalidade farmacológica, não farmacológica e cirúrgica. A viscossuplementação (ácido hialurônico intra-articular) se propõe a oferecer alívio dos sintomas e a possibilidade de adiamento da cirurgia. Este estudo estimou o impacto orçamentário entre a associação desse medicamento e o tratamento não cirúrgico (tratamento padrão), sob a perspectiva do Sistema Único de Saúde. Com base no pressuposto de que 5% dos portadores da doença seguem para tratamento e nos custos diretos das modalidades: farmacológica e não farmacológica foram calculados os cenários de referência e alternativos que compararam as diferentes opções de tratamento para um horizonte temporal de três anos. A análise principal estimou um impacto orçamentário incremental de aproximadamente R$ 126 milhões (1 ampola anual) e R$ 252 milhões (2 ampolas anuais). Já a diacereína, um condroprotetor oral, avaliada como uma opção alternativa, mostrou um impacto de R$ 334 milhões no orçamento em relação ao tratamento padrão, o que proporciona um aumento de 24% no custo em relação ao uso de 2 ampolas anuais de ácido hialurônico, tornando-a economicamente menos vantajosa. A viscossuplementação pode proporcionar maior qualidade de vida ao paciente, redução de custos para o sistema e otimização do fluxo de atendimento nas unidades de saúde. As estimativas apresentadas neste estudo podem auxiliar o gestor quanto à melhor utilização dos recursos financeiros e consequente tomada de decisão quanto à incorporação da tecnologia.


La osteoartritis de rodilla afecta a cerca de un 3,8% de la población mundial y se manifiesta por dolor, edema, rigidez y reducción de la función articular, impactando en la calidad de vida del paciente. El tratamiento consiste en la modalidad farmacológica, no farmacológica y quirúrgica. La viscosuplementación (ácido hialurónico intraarticular) se propone ofrecer un alivio de los síntomas y la posibilidad de un aplazamiento de la cirugía. Este estudio estimó el impacto presupuestario entre la asociación de este medicamento y el tratamiento no quirúrgico (tratamiento estándar), desde la perspectiva del Sistema Único de Salud. Basándonos en el supuesto de que un 5% de los portadores de la enfermedad siguen el tratamiento y en los costos directos de las modalidades tanto farmacológica, como no farmacológica, se calcularon los escenarios de referencia y alternativos que compararon las diferentes opciones de tratamiento para un horizonte temporal de tres años. El análisis principal estimó un impacto presupuestario incremental de aproximadamente BRL 126 millones (1 ampolla anual) y BRL 252 millones (2 ampollas anuales). En el caso de la diacereína, un condroprotector oral, evaluado como una opción alternativa, mostró un impacto de BRL 334 millones en el presupuesto, respecto al tratamiento estándar, lo que proporciona un aumento de un 24% en el costo, en relación con el uso de 2 ampollas anuales de ácido hialurónico, haciéndola económicamente menos ventajosa. La viscosuplementación puede proporcionar mayor calidad de vida al paciente, reducción de costes para el sistema y la optimización del flujo de atención en las unidades de salud. Las estimaciones presentadas en este estudio pueden ayudar al gestor en lo referente a una mejor utilización de los recursos financieros y, consecuentemente, en la toma de decisiones respecto a la incorporación de tecnología.


Assuntos
Ácido Hialurônico/uso terapêutico , Osteoartrite do Joelho/tratamento farmacológico , Viscossuplementação/economia , Viscossuplementos/uso terapêutico , Brasil/epidemiologia , Orçamentos , Humanos , Programas Nacionais de Saúde , Osteoartrite do Joelho/epidemiologia , Prevalência
13.
Acta ortop. mex ; 33(3): 166-168, may.-jun. 2019.
Artigo em Espanhol | LILACS | ID: biblio-1248656

RESUMO

Resumen: Introducción: La osteoartrosis es actualmente la quinta causa de discapacidad en el adulto. Su prevalencia aumenta a partir de los 40 años. La viscosuplementación es un tratamiento para las etapas iniciales de la osteoartrosis de rodilla. Objetivo: Comparar la eficacia y la calidad de vida en pacientes con gonartrosis sintomática tratados con ácido hialurónico de alto y mediano peso molecular. Material y métodos: Estudio analítico, retrospectivo, transversal, observacional de expedientes clínicos de pacientes con diagnóstico de gonartrosis grado II y grado III, de Octubre de 2017 a Junio de 2018, tratados con viscosuplementación con ácido hialurónico de alto o de mediano peso molecular; se analizó la calidad de vida y la escala de WOMAC de manera previa a la primera aplicación y con seguimiento a los dos, cuatro y seis meses. Resultados: 194 pacientes, con edades entre 30 y 87 años (promedio 61.85; DE = 11.3); 134 mujeres (69.1%) y 60 hombres (30.9%). En ambos grupos la evolución fue hacia la mejoría, con disminución en el puntaje WOMAC, sin diferencia significativa entre grupos. El puntaje de WOMAC tuvo un aumento mínimo pasados seis meses de la aplicación en ambos grupos, lo que se interpreta como disminución del efecto terapéutico. Dos pacientes tuvieron reacciones adversas mínimas localizadas, las cuales se resolvieron con medidas generales. Conclusión: El ácido hialurónico en ambas presentaciones, de alto y de bajo peso molecular, es efectivo en el tratamiento de la gonartrosis sintomática sin diferencia con el peso molecular.


Abstract: Introduction: OA is currently the fifth leading cause of adult disability, its prevalence increases from age 40. Viscosupplementation is a treatment for the early stages of knee OA. Objective: To compare efficacy and quality of life in patients with symptomatic gonartrosis, treated with high and low molecular weight hyaluronic acid. Material and methods: Analytical, retrospective, cross-sectional, observational study of clinical records of patients diagnosed with grade II and grade III gonarthrosis, October 2017 to June 2018, treated with viscosupplementation with high molecular weight hyaluronic acid or low molecular weight; WOMAC quality of life and scale were analyzed prior to the first application and tracked at two, four and six months. Results: 194 patients, aged between 30 to 87 years (promedio 61.85; SD = 11.3); 134 women (69.1%), 60 men (30.9%). In both groups the evolution was towards improvement, with a decrease in the WOMAC score, with no significant difference between groups. The WOMAC score had a minimum increase after 6 months of application in both groups, which is interpreted as decreasing the therapeutic effect. Two patients had localized minimal adverse reactions which were resolved with general measures. Conclusion: Hyaluronic acid in both presentations, high and low molecular weight, are effective in the treatment of symptomatic goonarthrosis without difference to molecular weight.


Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Idoso de 80 Anos ou mais , Osteoartrite do Joelho/terapia , Viscossuplementação , Qualidade de Vida , Estudos Transversais , Estudos Retrospectivos , Resultado do Tratamento , Ácido Hialurônico , Injeções Intra-Articulares , Pessoa de Meia-Idade , Peso Molecular
14.
Acta Ortop Mex ; 33(3): 166-168, 2019.
Artigo em Espanhol | MEDLINE | ID: mdl-32246608

RESUMO

INTRODUCTION: OA is currently the fifth leading cause of adult disability, its prevalence increases from age 40. Viscosupplementation is a treatment for the early stages of knee OA. OBJECTIVE: To compare efficacy and quality of life in patients with symptomatic gonartrosis, treated with high and low molecular weight hyaluronic acid. MATERIAL AND METHODS: Analytical, retrospective, cross-sectional, observational study of clinical records of patients diagnosed with grade II and grade III gonarthrosis, October 2017 to June 2018, treated with viscosupplementation with high molecular weight hyaluronic acid or low molecular weight; WOMAC quality of life and scale were analyzed prior to the first application and tracked at two, four and six months. RESULTS: 194 patients, aged between 30 to 87 years (promedio 61.85; SD = 11.3); 134 women (69.1%), 60 men (30.9%). In both groups the evolution was towards improvement, with a decrease in the WOMAC score, with no significant difference between groups. The WOMAC score had a minimum increase after 6 months of application in both groups, which is interpreted as decreasing the therapeutic effect. Two patients had localized minimal adverse reactions which were resolved with general measures. CONCLUSION: Hyaluronic acid in both presentations, high and low molecular weight, are effective in the treatment of symptomatic goonarthrosis without difference to molecular weight.


INTRODUCCIÓN: La osteoartrosis es actualmente la quinta causa de discapacidad en el adulto. Su prevalencia aumenta a partir de los 40 años. La viscosuplementación es un tratamiento para las etapas iniciales de la osteoartrosis de rodilla. OBJETIVO: Comparar la eficacia y la calidad de vida en pacientes con gonartrosis sintomática tratados con ácido hialurónico de alto y mediano peso molecular. MATERIAL Y MÉTODOS: Estudio analítico, retrospectivo, transversal, observacional de expedientes clínicos de pacientes con diagnóstico de gonartrosis grado II y grado III, de Octubre de 2017 a Junio de 2018, tratados con viscosuplementación con ácido hialurónico de alto o de mediano peso molecular; se analizó la calidad de vida y la escala de WOMAC de manera previa a la primera aplicación y con seguimiento a los dos, cuatro y seis meses. RESULTADOS: 194 pacientes, con edades entre 30 y 87 años (promedio 61.85; DE = 11.3); 134 mujeres (69.1%) y 60 hombres (30.9%). En ambos grupos la evolución fue hacia la mejoría, con disminución en el puntaje WOMAC, sin diferencia significativa entre grupos. El puntaje de WOMAC tuvo un aumento mínimo pasados seis meses de la aplicación en ambos grupos, lo que se interpreta como disminución del efecto terapéutico. Dos pacientes tuvieron reacciones adversas mínimas localizadas, las cuales se resolvieron con medidas generales. CONCLUSIÓN: El ácido hialurónico en ambas presentaciones, de alto y de bajo peso molecular, es efectivo en el tratamiento de la gonartrosis sintomática sin diferencia con el peso molecular.


Assuntos
Osteoartrite do Joelho , Viscossuplementação , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Humanos , Ácido Hialurônico , Injeções Intra-Articulares , Masculino , Pessoa de Meia-Idade , Peso Molecular , Osteoartrite do Joelho/terapia , Qualidade de Vida , Estudos Retrospectivos , Resultado do Tratamento
15.
Cad. Saúde Pública (Online) ; 35(10): e00098618, 2019. tab
Artigo em Português | LILACS | ID: biblio-1039384

RESUMO

Resumo: A osteoartrite de joelho afeta cerca de 3,8% da população mundial e se manifesta por dor, edema, rigidez e redução da função articular, impactando na qualidade de vida do paciente. O tratamento consiste na modalidade farmacológica, não farmacológica e cirúrgica. A viscossuplementação (ácido hialurônico intra-articular) se propõe a oferecer alívio dos sintomas e a possibilidade de adiamento da cirurgia. Este estudo estimou o impacto orçamentário entre a associação desse medicamento e o tratamento não cirúrgico (tratamento padrão), sob a perspectiva do Sistema Único de Saúde. Com base no pressuposto de que 5% dos portadores da doença seguem para tratamento e nos custos diretos das modalidades: farmacológica e não farmacológica foram calculados os cenários de referência e alternativos que compararam as diferentes opções de tratamento para um horizonte temporal de três anos. A análise principal estimou um impacto orçamentário incremental de aproximadamente R$ 126 milhões (1 ampola anual) e R$ 252 milhões (2 ampolas anuais). Já a diacereína, um condroprotetor oral, avaliada como uma opção alternativa, mostrou um impacto de R$ 334 milhões no orçamento em relação ao tratamento padrão, o que proporciona um aumento de 24% no custo em relação ao uso de 2 ampolas anuais de ácido hialurônico, tornando-a economicamente menos vantajosa. A viscossuplementação pode proporcionar maior qualidade de vida ao paciente, redução de custos para o sistema e otimização do fluxo de atendimento nas unidades de saúde. As estimativas apresentadas neste estudo podem auxiliar o gestor quanto à melhor utilização dos recursos financeiros e consequente tomada de decisão quanto à incorporação da tecnologia.


Abstract: Knee osteoarthritis affects 3.8% of the world population and manifests as pain, edema, stiffness, and reduced joint function, impacting the patient's quality of life. Treatment consists of the pharmacological, non-pharmacological, and surgical modalities. Viscosupplementation (intraarticular hyaluronate) has been proposed to relieve symptoms and potentially postpone surgery. This study estimated the budget impact of the association of this drug and non-surgical treatment (standard treatment) from the perspective of the Brazilian Unified National Health System. Based on the assumption that 5% of patients proceed to treatment and on the direct costs of the pharmacological and non-pharmacological modalities, the authors calculated the reference and alternative scenarios that compared the different treatment options in a three-year timeline. The principal analysis estimated an incremental budget impact of approximately BRL 126 million (U$ 32 million) for one vial of hyaluronate a year and BRL 252 million (USD 64 million) for two vials a year. Diacerein, an oral chondroprotector, assessed as an alternative, showed a budget impact of BRL 334 million (USD 86 million) in relation to standard treatment, representing a 24% cost increase compared to two vials a year of hyaluronate, making it less economically advantageous. Viscosupplementation can provide better quality of life for patients, reduce costs for the health system, and optimize the flow of care in health services. The estimates presented in this study can assist administrators in the best use of resources and thus in decision-making on the technology's incorporation.


Resumen: La osteoartritis de rodilla afecta a cerca de un 3,8% de la población mundial y se manifiesta por dolor, edema, rigidez y reducción de la función articular, impactando en la calidad de vida del paciente. El tratamiento consiste en la modalidad farmacológica, no farmacológica y quirúrgica. La viscosuplementación (ácido hialurónico intraarticular) se propone ofrecer un alivio de los síntomas y la posibilidad de un aplazamiento de la cirugía. Este estudio estimó el impacto presupuestario entre la asociación de este medicamento y el tratamiento no quirúrgico (tratamiento estándar), desde la perspectiva del Sistema Único de Salud. Basándonos en el supuesto de que un 5% de los portadores de la enfermedad siguen el tratamiento y en los costos directos de las modalidades tanto farmacológica, como no farmacológica, se calcularon los escenarios de referencia y alternativos que compararon las diferentes opciones de tratamiento para un horizonte temporal de tres años. El análisis principal estimó un impacto presupuestario incremental de aproximadamente BRL 126 millones (1 ampolla anual) y BRL 252 millones (2 ampollas anuales). En el caso de la diacereína, un condroprotector oral, evaluado como una opción alternativa, mostró un impacto de BRL 334 millones en el presupuesto, respecto al tratamiento estándar, lo que proporciona un aumento de un 24% en el costo, en relación con el uso de 2 ampollas anuales de ácido hialurónico, haciéndola económicamente menos ventajosa. La viscosuplementación puede proporcionar mayor calidad de vida al paciente, reducción de costes para el sistema y la optimización del flujo de atención en las unidades de salud. Las estimaciones presentadas en este estudio pueden ayudar al gestor en lo referente a una mejor utilización de los recursos financieros y, consecuentemente, en la toma de decisiones respecto a la incorporación de tecnología.


Assuntos
Humanos , Osteoartrite do Joelho/tratamento farmacológico , Viscossuplementos/uso terapêutico , Viscossuplementação/economia , Ácido Hialurônico/uso terapêutico , Brasil/epidemiologia , Orçamentos , Prevalência , Osteoartrite do Joelho/epidemiologia , Programas Nacionais de Saúde
16.
Pain Res Manag ; 2018: 5392538, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30154944

RESUMO

Viscosupplementation is a minimally invasive technique that replaces synovial fluid by intra-articular injection of hyaluronic acid (HA). Although effective in some joints, there is not conclusive evidence regarding temporomandibular disorders. This case series described the efficacy of a viscosupplementation protocol in intra-articular temporomandibular disorders. Ten patients with a diagnosis of disc displacement and/or osteoarthritis by Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) were submitted to four monthly injections of low or medium molecular weight HA. Pain, mandibular function, image analysis by tomography and magnetic resonance, and quality of life were assessed at baseline and follow-ups (1 and 6 months). Pain, jaw range-of-motion, mandibular function, and quality of life improved at follow-up evaluations. Osteoarthritis changes decreased, and 20% of patients improved mandibular head excursion after treatment. Resolution of effusion and improvement in disc morphology were observed for most patients. This viscosupplementation protocol reduced pain and symptoms associated with internal derangement of temporomandibular joint, improved quality of life, and showed benefits from both low and medium molecular weight HA in alternate cycles.


Assuntos
Ácido Hialurônico/uso terapêutico , Transtornos da Articulação Temporomandibular/tratamento farmacológico , Viscossuplementação/métodos , Viscossuplementos/uso terapêutico , Adulto , Idoso , Feminino , Seguimentos , Humanos , Injeções Intra-Articulares , Angiografia por Ressonância Magnética , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Osteoartrite/etiologia , Osteoartrite/terapia , Manejo da Dor , Índice de Gravidade de Doença , Transtornos da Articulação Temporomandibular/diagnóstico por imagem , Adulto Jovem
17.
Int Orthop ; 41(11): 2273-2280, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-28856435

RESUMO

PURPOSE: To analyze the early outcomes of viscosupplementation in patients with severe knee osteoarthritis. METHOD: A randomized, double-blind clinical trial of 143 knees divided into three groups: Group 1 - intra-articular injection of triamcinolone; Group 2 - hylan GF20; and Group 3 - triamcinolone + hylan GF20. Outcomes were evaluated using Lysholm and KSS scores before treatment and after one, three and six months. RESULTS: Within-group comparisons revealed improvements in Lysholm scores in all groups in the one month evaluation relative to pre-treatment levels (p < 0.01). This improvement was maintained in the third month after treatment (p > 0.05). Scores at six months were significantly lower than those observed in the previous follow-up assessments (p < 0.05), but still higher than pre-treatment levels (p < 0.05). KSS scores also improved after one month relative to pre-treatment levels (p < 0.01). This improvement was still present at three and six months after treatment in the corticosteroid group (p > 0.05). Patients treated with hylan GF20 showed lower scores in the last evaluation relative to month one (p < 0.05). No significant differences were observed between the treatment groups (p > 0.05). CONCLUSIONS: Viscosupplementation increased functional scores in patients with severe osteoarthritis of the knee, especially within three months of injection. However, it was not superior to the use of triamcinolone.


Assuntos
Ácido Hialurônico/análogos & derivados , Osteoartrite do Joelho/terapia , Viscossuplementação/métodos , Viscossuplementos/uso terapêutico , Método Duplo-Cego , Feminino , Seguimentos , Glucocorticoides/uso terapêutico , Humanos , Ácido Hialurônico/uso terapêutico , Injeções Intra-Articulares , Articulação do Joelho/fisiopatologia , Masculino , Osteoartrite do Joelho/fisiopatologia , Resultado do Tratamento , Triancinolona/uso terapêutico
18.
Acta fisiátrica ; 24(3): 127-132, set. 2017. tab
Artigo em Inglês | LILACS | ID: biblio-968422

RESUMO

The viscosupplementation and strength training are interventions accepted in the treatment of knee osteoarthritis. Objective: The study describes the effect of two interventions in quality of life and functional capacity. Method: Thirty women diagnosed with bilateral knee osteoarthritis of grade II and III by radiological criteria of Kellgren & Lawrence, were randomized into three groups with ten patients each: VSTF group submitted to viscosupplementation and strength training, TF group submitted only to strength training and VS group submitted only to viscossuplementation. Moments of the study were defined as pre-procedure (PRE), after 48 hours of VS (POS-VS) after 12 weeks of training (POS T) and after eight weeks of detraining (POS D). Quality of life was assessed by the SF-36 BRAZIL, functional capacity by Lequesne index. Intraarticular infiltrations were carried out with a single dose of 6 ml / 48 mg with 6,000,000 kDa Hylan GF-20 and strength training sessions were held for twelve weeks. Results: Strength training and viscosupplementation were effective in the treatment of knee osteoarthritis. Both interventions promoted improvements in quality of life and in functional capacity (p < 0.001), with advantage to the groups that trained force. Conclusion: Strength training is a possible replacement of viscosupplementation in the treatment of osteoarthritis of women's knees. However, the beneficial effect of viscosupplementation in pain reduction suggests better efficiency in the strength training execution which may be an advantage of the association of both


Assuntos
Qualidade de Vida , Osteoartrite do Joelho/terapia , Viscossuplementação/instrumentação , Treinamento Resistido/métodos , Método Duplo-Cego
19.
Int. j. morphol ; 35(3): 870-876, Sept. 2017. ilus
Artigo em Inglês | LILACS | ID: biblio-893066

RESUMO

The aim of this study was to perform a literature review regarding the role of hyaluronic acid (HA) in the homeostasis and therapeutics of temporomandibular joint (TMJ) osteoarthritis (OA). The TMJ has characteristics that give it special adaptation and recovery abilities, where HA plays a fundamental role in helping to maintain joint homeostasis, which is affected in pathological processes like OA. OA is a chronic degenerative multi-factor disease that can affect all the components of the synovial joints, causing degradation of the articular cartilage, extracellular matrix and breakage in the HA molecules. HA is a non-branched linear polysaccharide with viscosupplementation, anti-inflammatory, lubrication and pain relief effects; it also activates the intrinsic repair processes of the cartilage and normalizes the endogenous production of HA by the synoviocytes. In recent years, the therapeutic use of HA has shown evidence that supports its application in TMJ OA, improving viscosupplementation capacity, acting at the cellular and molecular levels, reducing various inflammatory mediators and improving the reparative characteristics. Its use has been studied in animal models and in humans. However, no consensus has been reached in terms of concentrations, dose, application frequency or molecular weight to be used.


El objetivo de este estudio fue realizar una revisión de la literatura respecto del rol del ácido hialurónico (AH) en la homeostasis y terapéutica de la osteoartritis (OA) de la articulación temporomandibular (ATM). La ATM presenta características que le confieren propiedades de adaptación y recuperación especiales, donde el AH juega un rol fundamental ayudando a mantener la homeostasis articular, la cual se ve afectada en procesos patológicos como la OA. La OA es una enfermedad multifactorial crónica degenerativa que puede afectar a todos los componentes de las articulaciones sinoviales, generando degradación del cartílago articular, matriz extracelular y quiebre de las moléculas de AH. El AH es un polisacárido lineal no ramificado que presenta efectos de viscosuplementación, antiinflamatorios, lubricantes, en el alivio del dolor, permite además, activar procesos intrínsecos de reparación del cartílago y normalizar la producción endógena de AH por parte de los sinoviositos. En los últimos años el uso terapéutico del AH ha presentado evidencia que sustenta su aplicación en OA de ATM mejorando la capacidad de viscosuplementación, actuando a nivel celular y molecular, disminuyendo diversos mediadores inflamatorios y mejorando las características reparativas. Su uso se ha estudiado en modelos animales y en humanos, sin embargo no existe consenso en cuanto a concentraciones, dosis, frecuencias de aplicación y peso molecular a utilizar.


Assuntos
Osteoartrite/tratamento farmacológico , Transtornos da Articulação Temporomandibular/tratamento farmacológico , Viscossuplementação/métodos , Ácido Hialurônico/administração & dosagem , Articulação Temporomandibular/efeitos dos fármacos , Homeostase/efeitos dos fármacos
20.
Rev Med Inst Mex Seguro Soc ; 55(1): 67-75, 2017.
Artigo em Espanhol | MEDLINE | ID: mdl-28092250

RESUMO

In the modern world, among the different clinical presentations of osteoarthritis, gonarthrosis and coxarthrosis exhibit the highest prevalence. In this paper, the characteristics of osteoarthritis and the different scales of assessment and classification of this pathology are exposed, to provide an exhibition of current evidence generated around diagnostic algorithms and treatment of osteoarthritis, with emphasis set out in the knee and hip, as these are the most frequent; a rational procedure for monitoring patients with osteoarthritis based on characteristic symptoms and the severity of the condition is also set. Finally, reference is made to the therapeutic benefits of the recent introduction of viscosupplementation with Hylan GF-20.


En el mundo moderno, de entre las distintas presentaciones clínicas de la osteoartrosis, la gonartrosis y la coxartrosis son las que exhiben las mayores prevalencias. En el presente artículo se enuncian los rasgos característicos de la osteoartrosis y las diferentes escalas de evaluación y clasificación de esta patología, para a continuación ofrecer una exposición de la evidencia actual generada en torno a los algoritmos de diagnóstico y terapéuticos de la osteoartrosis, con énfasis en la de rodilla y la de cadera por ser estas las de mayor frecuencia; también se establece un procedimiento racional para el seguimiento del paciente con osteoartrosis en función de la sintomatología característica y el grado de severidad del padecimiento. Finalmente, se alude a los beneficios terapéuticos de la reciente introducción de la viscosuplementación mediante Hilano GF-20.


Assuntos
Algoritmos , Tomada de Decisão Clínica , Osteoartrite/diagnóstico , Osteoartrite/terapia , Humanos , Ácido Hialurônico/análogos & derivados , Ácido Hialurônico/uso terapêutico , Índice de Gravidade de Doença , Viscossuplementação/métodos , Viscossuplementos/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA